CADTH | Evidence Driven
CADTH | Evidence Driven

enfortumab vedotin

Details

Generic Name:
enfortumab vedotin
Project Status:
Pending
Therapeutic Area:
Metastatic urothelial cancer
Manufacturer:
Seagen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Padcev
Project Line:
Reimbursement Review
Project Number:
PC0353-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​​In combination with pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
In combination with pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : April 9, 2024